A Phase 1 Study to Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis
Latest Information Update: 31 Jul 2023
Price :
$35 *
At a glance
- Drugs CS20AT04 (Primary)
- Indications Lupus nephritis
- Focus Adverse reactions
- Sponsors CORESTEM
- 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism
- 18 Nov 2019 Status changed from recruiting to completed.
- 08 Jun 2017 New trial record